Plink Tank | | Page 2

While I was working on the previous post (introducing the you-are-not-goo tool), I ran across a textbook case study for Tool #1, and a reminder of how useful this one simple rule can be. ABC News (the Australian Broadcasting Company) online ran an article reporting on an experiment involving nano-sized metals (like the type commonly used in sunblocks and mineral makeup, but in this case involving metals used in artificial joints). The ABC headline, “More evidence nanoparticles damage DNA”, is worrying enough. And the outcome of the experiment, suggesting that nanoparticle metals can damage even cells they don’t directly touch, only reinforces that anxiety. Given that “DNA damage” is shorthand for “increased cancer risk”, and that nanoparticles are now widespread in the personal products market, what’s not to fear?

Remember these guys?

Remember these guys?

But as I continued to read the article, I noticed something. The descriptions of the experiment and findings mentioned only cells, or layers of cells, or tissues. All that talk of cell membranes but nary a mention of mice or men? It was a big red flag that this was investigational or exploratory research, and not a well-designed study on humans. In other words, the report was a perfect case for applying Tool #1.

So, I spent all of thirty seconds on Google, hoping that another service had picked up the story and furnished better analysis. And I was promptly rewarded! Read More »

Posted in Plink, Toolkit | Leave a comment

ToolBoxAt the risk of getting fire-bombed by PETA, let me describe Tool #1 this way: test tube goo and lab rats are not people. This seems pretty self-evident, doesn’t it? Yet you’ll be amazed (and infuriated) at how many breathless media reports of fabulous new discoveries don’t bother to explain whether the miracle in question worked for people, rats, or a glob of cells in a petri dish. This is the first and most fundamental tool for evaluating a news report, whether you’re reading about it in the USA Today or in a medical journal, and you should actively seek out this information. (In fairness, if you’re reading a medical or science journal article, it’ll be impossible to miss.)

Amazing Cancer Cure….for Rats

To understand just how important this factor is, consider this: fully 95% of new cancer drugs that looked oh-so-promising in test tubes or in lab rats fail by the clinical trial phase. And while other drugs do a little better (e.g., heart drugs fail at a “mere” 70% by phase III clinical trials), they still fail more than half the time. Read More »

Posted in Toolkit | 2 Comments

Last weekend I met an actual, real-life cancer researcher, at an NBCC ProjectLEAD workshop. She was smart, and pretty, and earnest — sort of how you imagine cancer researchers when you’re sitting there with your chemo I.V. running and wondering who dreamed up that wonderful-wretched drug. In the course of conversation, I asked her about Tykerb (generic name: lapatinib), a new “targeted” biologic chemotherapy drug. And when she mentioned that researchers originally had high hopes that it would cause few if any side effects, I snorted.

I think I offended her, for which I’m truly sorry. But if I had a nickel for every fabulous new targeted, biologic, super-earth-shattering drug that was supposed to zero-in on cancer cells with minimal side-effects….well, you know the rest.

Let’s just say that the influence of desperate hope, fervent desire, and even ego is often too much for our poor, unappreciated critical faculties, even if you have MD, PhD, or Uber-Mensa on your name tag. And how much more so for we mere mortals?

All the more reason for a handy tool kit! Read More »

Posted in Toolkit | Leave a comment

If anything can be said for breast self-exams, it’s that they inspire some crazy fun videos. But the latest news suggests that, for most of us, that may be all they deliver. If this sounds as crazy to you as it did to me, read on.

Last weekend I attended a two and a half day ProjectLEAD workshop organized by the National Breast Cancer Coalition (NBCC). While my family was arduously touring Washington’s apple country and subjecting themselves to gallons of cider, I was basking in a series of (how to put this?) content-dense lectures on the molecular biology, epidemiology, and politics of breast cancer. (And worshiping the coffee urn…)

Strangely enough, it was the NBCC’s breast self-exam “myth buster” that gave me a mental hernia. Read More »

Posted in Breast Cancer | Leave a comment
The Original Antoinette

The Original Antoinette

What do you get when you cross Marie Antoinette with a natural food conglomerate? If you guessed an out-of-touch tofu tycoon spouting “Let them eat organic beets,” you win!

Earlier this summer Whole Foods CEO John Mackey came out with a pompous polemic on health care reform, complete with his very own epidemiological theories. If you’re not a Whole Foods shopper or critic, you may well have missed it. And, by the time this posts, we may be close to a unified health care reform bill. But the subject won’t go away even then, so it’s worth revisiting this textbook example of what’s wrong with the health reform debate. Namely, that it’s been taken over by gibberish.

John Mackey, channeling Antoinette

John Mackey, channeling Antoinette

By way of illustration, I decided to take a chapter out of Mackey’s nutty manual, along with his kooky logic and reliance on non-scientific observation, and formulate my own theory about lifestyle and disease.

Read More »

Posted in Health Care Reform, Plink | 2 Comments

One of the ugliest features of the health care debate, aside from the media’s willingness to spread unadulterated garbage (death panels, anyone?), is that otherwise smart, thoughtful people are weighing in with boatloads of nonsense. Catching up on my reading a few weeks ago I ran across this rambling and conclusory post by Megan McArdle, about the “dangers” of government-administered health care. Here, in a typical comment, is what she has to say about cancer care in Britain:

Agencies like Britain’s NICE are a case in point. As long as people don’t know that there are cancer treatments they’re not getting, they’re happy. Once they find out, satisfaction plunges. But the reason that people in Britain know about things like Herceptin for early stage breast cancer is a robust private market in the US that experiments with this sort of thing.

(Sigh…where even to begin?)

Read More »

Posted in Health Care Reform, Plink | Leave a comment

tweet feed